Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors

Oncogene

Volumn 28, Issue 2, 2009, Pages 157-169

  Smith, J R ^a   Clarke, P A ^a   De Billy, E ^a   Workman, P ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

17 AAG; CDC37; Client; Cochaperone; HSP90

Indexed keywords

CELL CYCLE PROTEIN 37; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90 INHIBITOR; PHOSPHOTRANSFERASE; PROTEASOME; PROTEIN KINASE B; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; ENZYME DEGRADATION; ENZYME STABILITY; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADENOCARCINOMA; APOPTOSIS; BENZOQUINONES; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE, TUMOR; CHAPERONINS; COLONIC NEOPLASMS; FEMALE; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TARGETING; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MALE; NEOPLASM PROTEINS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRAZOLES; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 58249112898     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.380     Document Type: Article

References (62)

1. Banerji U, Affolter A, Judson I, Marais R, Workman P. (2008). BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. Mol Cancer Ther 7: 737-739.
2. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y et al. (2005). Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23: 4152-4161.
3. Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. (2002). Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 277: 39858-39866.
4. Caplan AJ, Mandal AK, Theodoraki MA. (2007). Molecular chaperones and protein kinase quality control. Trends Cell Biol 17: 87-92.
5. Chen S, Smith DF. (1998). Hop as an adaptor in the heat shock protein 70 (Hsp70) and hsp90 chaperone machinery. J Biol Chem 273: 35194-35200.
6. Clarke PA, Hostein I, Banerji U, Stefano FD, Maloney A, Walton M et al. (2000). Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene 19: 4125-4133.
7. Connell P, Ballinger CA, Jiang J, Wu Y, Thompson LJ, Hohfeld J et al. (2001). The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol 3: 93-96.
8. da Rocha DS, Friedlos F, Light Y, Springer C, Workman P, Marais R. (2005). Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 65: 10686-10691.
9. Fang Y, Fliss AE, Rao J, Caplan AJ. (1998). SBA1 encodes a yeast hsp90 cochaperone that is homologous to vertebrate p23 proteins. Mol Cell Biol 18: 3727-3734.
10. Ghatak S, Misra S, Toole BP. (2005). Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. J Biol Chem 280: 8875-8883.
11. Grammatikakis N, Lin JH, Grammatikakis A, Tsichlis PN, Cochran BH. (1999). p50(cdc37) acting in concert with Hsp90 is required for Raf-1 function. Mol Cell Biol 19: 1661-1672.
12. Gray Jr PJ, Prince T, Cheng J, Stevenson MA, Calderwood SK. (2008). Targeting the oncogene and kinome chaperone CDC37. Nat Rev Cancer 8: 491-495.
13. Gray Jr PJ, Stevenson MA, Calderwood SK. (2007). Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells. Cancer Res 67: 11942-11950.
14. Grbovic OM, Basso AD, Sawai A, Ye Q, Friedlander P, Solit D et al. (2006). V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci USA 103: 57-62.
15. Guo F, Rocha K, Bali P, Pranpat M, Fiskus W, Boyapalle S et al. (2005). Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res 65: 10536-10544.
16. Hartson SD, Irwin AD, Shao J, Scroggins BT, Volk L, Huang W et al. (2000). p50(cdc37) is a nonexclusive Hsp90 cohort which participates intimately in Hsp90-mediated folding of immature kinase molecules. Biochemistry 39: 7631-7644.
17. Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A et al. (2006). Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 10: 321-330.
18. Holford J, Sharp SY, Murrer BA, Abrams M, Kelland LR. (1998). In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer 77: 366-373.
19. Holmes JL, Sharp SY, Hobbs S, Workman P. (2008). Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17- demethoxygeldanamycin. Cancer Res 68: 1188-1197.
20. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. (2001). Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17- demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 61: 4003-4009.
21. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC et al. (2003). A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425: 407-410.
22. Lamphere L, Fiore F, Xu X, Brizuela L, Keezer S, Sardet C et al. (1997). Interaction between Cdc37 and Cdk4 in human cells. Oncogene 14: 1999-2004.
23. Lavictoire SJ, Parolin DA, Klimowicz AC, Kelly JF, Lorimer IA. (2003). Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII. J Biol Chem 278: 5292-5299.
24. Lee P, Rao J, Fliss A, Yang E, Garrett S, Caplan AJ. (2002). The Cdc37 protein kinase-binding domain is sufficient for protein kinase activity and cell viability. J Cell Biol 159: 1051-1059.
25. MacLean M, Picard D. (2003). Cdc37 goes beyond Hsp90 and kinases. Cell Stress Chaperones 8: 114-119.
26. Maloney A, Workman P. (2002). HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2: 3-24.
27. Mandal AK, Lee P, Chen JA, Nillegoda N, Heller A, DiStasio S et al. (2007). Cdc37 has distinct roles in protein kinase quality control that protect nascent chains from degradation and promote posttranslational maturation. J Cell Biol 176: 319-328.
28. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. (2002). The protein kinase complement of the human genome. Science 298: 1912-1934.
29. McDonald E, Workman P, Jones K. (2006). Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancer. Curr Top Med Chem 6: 1091-1107.
30. Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R et al. (2007). Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 25: 5410-5417.
31. Obermann WM, Sondermann H, Russo AA, Pavletich NP, Hartl FU. (1998). In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis. J Cell Biol 143: 901-910.
32. Pacey S, Banerji U, Judson I, Workman P. (2006). Hsp90 inhibitors in the clinic. Handb Exp Pharmacol 172: 331-358.
33. Panaretou B, Siligardi G, Meyer P, Maloney A, Sullivan JK, Singh S et al. (2002). Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol Cell 10: 1307-1318.
34. Pearl LH. (2005). Hsp90 and Cdc37 - a chaperone cancer conspiracy. Curr Opin Genet Dev 15: 55-61.
35. Pearl LH, Prodromou C. (2006). Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 75: 271-294.
36. Pearl LH, Prodromou C, Workman P. (2008). The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 410: 439-453.
37. Powers MV, Clarke PA, Workman P. (2008). Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 14: 250-262.
38. Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S et al. (2007). Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 67: 5840-5850.
39. Roe SM, Ali MM, Meyer P, Vaughan CK, Panaretou B, Piper PW et al. (2004). The Mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell 116: 87-98.
40. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, Pearl LH. (1999). Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 42: 260-266.
41. Sato S, Fujita N, Tsuruo T. (2000). Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 97: 10832-10837.
42. Schwarze SR, Fu VX, Jarrard DF. (2003). Cdc37 enhances proliferation and is necessary for normal human prostate epithelial cell survival. Cancer Res 63: 4614-4619.
43. Sharp SY, Prodromou C, Boxall K, Powers MV, Holmes JL, Box G et al. (2007). Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol Cancer Ther 6: 1198-1211.
44. Siligardi G, Hu B, Panaretou B, Piper PW, Pearl LH, Prodromou C. (2004). Co-chaperone regulation of conformational switching in the Hsp90 ATPase cycle. J Biol Chem 279: 51989-51998.
45. Siligardi G, Panaretou B, Meyer P, Singh S, Woolfson DN, Piper PW et al. (2002). Regulation of Hsp90 ATPase activity by the cochaperone Cdc37p/p50cdc37. J Biol Chem 277: 20151-20159.
46. Smith JR, Workman P. (2007). Targeting the cancer chaperone HSP90. Drug Discov Today: Ther Strategies 4: 219-227.
47. Stepanova L, Finegold M, DeMayo F, Schmidt EV, Harper JW. (2000a). The oncoprotein kinase chaperone CDC37 functions as an oncogene in mice and collaborates with both c-myc and cyclin D1 in transformation of multiple tissues. Mol Cell Biol 20: 4462-4473.
48. Stepanova L, Leng X, Harper JW. (1997). Analysis of mammalian Cdc37, a protein kinase targeting subunit of heat shock protein 90. Methods Enzymol 283: 220-229.
49. Stepanova L, Leng X, Parker SB, Harper JW. (1996). Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev 10: 1491-1502.
50. Stepanova L, Yang G, DeMayo F, Wheeler TM, Finegold M, Thompson TC et al. (2000b). Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia. Oncogene 19: 2186-2193.
51. Turnbull EL, Martin IV, Fantes PA. (2005). Cdc37 maintains cellular viability in Schizosaccharomyces pombe independently of interactions with heat-shock protein 90. FEBS J 272: 4129-4140.
52. Vaughan CK, Gohlke U, Sobott F, Good VM, Ali MM, Prodromou C et al. (2006). Structure of an Hsp90-Cdc37-Cdk4 complex. Mol Cell 23: 697-707.
53. Wang H, Goode T, Iakova P, Albrecht JH, Timchenko NA. (2002). C/EBP alpha triggers proteasome-dependent degradation of cdk4 during growth arrest. EMBO J 21: 930-941.
54. Westerheide SD, Bosman JD, Mbadugha BN, Kawahara TL, Matsumoto G, Kim S et al. (2004). Celastrols as inducers of the heat shock response and cytoprotection. J Biol Chem 279: 56053-56060.
55. Workman P. (2004). Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett 206: 149-157.
56. Workman P, Burrows F, Neckers L, Rosen N. (2007). Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann NY Acad Sci 1113: 202-216.
57. Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C, Neckers L. (2002). Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci USA 99: 12847-12852.
58. Xu W, Yuan X, Jung YJ, Yang Y, Basso A, Rosen N et al. (2003). The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells. Cancer Res 63: 7777-7784.
59. Yang H, Chen D, Cui QC, Yuan X, Dou QP. (2006). Celastrol, a triterpene extracted from the Chinese 'Thunder of God Vine,' is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 66: 4758-4765.
60. Yun BG, Matts RL. (2005). Differential effects of Hsp90 inhibition on protein kinases regulating signal transduction pathways required for myoblast differentiation. Exp Cell Res 307: 212-223.
61. Zhang T, Hamza A, Cao X, Wang B, Yu S, Zhan CG et al. (2008). A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 7: 162-170.
62. Zhang W, Hirshberg M, McLaughlin SH, Lazar GA, Grossmann JG, Nielsen PR et al. (2004). Biochemical and structural studies of the interaction of Cdc37 with Hsp90. J Mol Biol 340: 891-907.